Renal failure and the concomitant derangement of micronutrient metabolism

Nutrition in Clinical Practice

Volumn 14, Issue 5, 1999, Pages 238-246

  Makoff, Rhoda ^a   Gonick, Harvey ^b  

^a R and D Laboratories Inc   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0006985306     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/088453369901400505     Document Type: Article

References (105)

1. Rocco M, MakofF R: Appropriate vitamin therapy for dialysis patients. Sem Dial 10:272-277, 1997.
2. Stein G, Sperschneider S, Koppe S: Vitamin levels in chronic renal failure and need for supplementation. Blood Purif 3:52-62, 1985.
3. Gallieni M, Brancaccio D, Cozzolino M, et al: Trace elements in renal failure: are they clinically important? Nephrol Dial Transplant 11:1232-1235, 1996.
4. 12 or folic acid absorption or utilization. Am J Med 48:599-608, 1970.
5. 6 deficiency in uremia. Am J Clin Nutr 28:950-957, 1975.
6. Drueke TB: Resistance to recombinant human erythropoietin in hemodialysis patients. Am J Nephrol 10(Supp2):34-39, 1990.
7. Pronai W, Riegler-Keil M, Silberbauer K, et al: Folic acid supplementation improves erythropoietin response. Nephron 71:395-400, 1995.
8. Makoff R, Dwyer J, Rocco MV: Folic acid, pyridoxine, cobalamin and homocysteine and their relationship to cardiovascular disease in end-stage renal disease. J Renal Nutri 6:2-11, 1996.
9. Bostom AG, Culleton BF: Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol; 10:1-10, 1999.
10. McCully KS: Vascular pathology of homocysteinemia: Implications for pathogenesis of arteriosclerosis. Am J Pathol 56:111-128, 1969.
11. Steiner A: The effect of choline on the production of experimental atherosclerosis in rabbits. Proc Soc Exp Biol Med 38:231-233, 1938.
12. Hartoff WE, Ridout JH, Sellers EA, et al: Atheromatous changes in aorta, carotid and coronary arteries of choline deficient Rats. Proc Soc Exp Biol Med 81:384-393, 1952.
13. Ueland PM, Refsum H, Brattstrom L: Plasma homocysteine and cardiovascular disease. IN Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function, Francis Jr RB (ed). Dekker, New York, 1992, pp 183-236.
14. Smolin LA, Benevenga NGH: Accumulation of homocysteine in vitamin B6 deficiency: A model for the study of cystathionine p synthase deficiency. J Nutri 112:1264-1272, 1982.
15. Peterson JC, Spence JD: Vitamins and the progression of atherosclerosis in hyperhomocysteinemia. Lancet 351:263, 1998.
16. Norris SH, Kurtzman NA: Minimizing anemia in the chronic hemodiaysis patient. Int Artif Organs 9:199-208, 1986.
17. Kopple JD, Mercurio K, Blumenkrantz MJ, et al: Daily requirement for pyridoxine supplementation in chronic renal failure. Kidney Int 19:694-704, 1981.
18. 6 requirements of patients on chronic periotoneal dialysis. Kidney Int 36:702-706, 1989.
19. 12 could hurt seniors: Tufts Nutri Lett 9:11, 1992.
20. House AA, Donnelly JG: Effect of multivitamins on plasma homocysteine and folate levels in patients on hemodialysis. ASAIO J 45:94-97, 1999.
21. Hida MM, Jufii H, Satoh T: Vitamin and mineral status in chronic renal failure-the effect of protein restriction. Nippon Jinzo Gakkai Shi 36:740-745, 1994.
22. Pietrazak I: Vitamin disturbances in chronic renal insufficiency. I. Water soluble vitamins. Przegl Lek 52:522-525, 1995.
23. Jung U, Helbich-Endermann M, Bitsch R, et al: Are patients with chronic renal failure (CRF) deficient in biotin and is regular biotin supplementation required? Z Ernahrungswiss 37:363-367, 1998.
24. Rocco MV, Poole D, Poindexter P, et al: Intake of vitamins and minerals in stable hemodialysis patients as determined by nine-day food records. J Renal Nutri 7:17-24, 1997.
25. Allman MA, Truswell AS, Tiller DJ, et al: Vitamin supplementation of patients receiving hemodialysis. Med J Aust 150:130-133, 1989.
26. Tomson CRV, Channon SM, Parkinson IS, et al: Correction of sub-clinical ascorbate deficiency in patients receiving dialysis: Effects on plasma oxalate, serum cholesterol and capillary fragility. Clin Chem Acta 180:255-264, 1989.
27. Costello JF, Sadovnic MJ, Cottington EM: Plasma oxalate levels rise in hemodialysis patients despite increased oxalate removal. J Am Soc Nephrol 1:1289-1298, 1991.
28. Thompson CS, Weinman EJ: The secondary oxalosis of renal failure. Sem in Dial :94-99, 1988.
29. Pru C, Eaton J, Kjellstrand C: Vitamin C intoxication and hyperoxalemia in chronic hemodialysis patients. Nephron 39:112-116, 1985.
30. Shah GM, Ross EAL, Sabo A et al: Effects of ascorbic acid and pyridoxine supplementation on oxalate metabolism in peritoneal dialysis patients. Am J Kid Dis 20:42-49, 1992.
31. Yatzidis H, Digenis P, Fountas P: Hypervitaminosis A accompanying advanced chronic renal failure. Brit Med J 3:352-353, 1975.
32. Muth I: Implications of Hypervitaminosis A in chronic renal failure. J Renal Nutri 1:2-8, 1991.
33. Fishbane S, Frei GL, Finger M, et al: Hypervitaminosis A in two hemodialysis patients. Am J Kidney Dis 25:346-349, 1995.
34. Gleghorn E, Eisenberg L, Hack S, et al: Observations of vitamin A toxicity in three patients with renal failure receiving parenteral alimentation. Am J Clin Nutri 44:107-112, 1986.
35. Duffy TP: Remembering the ABC's. New Engl J Med 330994-996, 1994.
36. Pastor MC, Sierra C, Bonal J, et al: Serum and erythrocyte tocopherol in uremic patients: Effect of hemodialysis versus peritoneal dialysis. Am J Nephrol 13:238-243, 1993.
37. Cohen JD, Vilijoen M, Clifford D, et al: Plasma vitamin E levels, in a chronically hemolyzing group of dialysis patients. Clin Nephrol 25:42-47, 1986.
38. Ono K: Effects of large dose vitamin E supplementation on anemia in hemodialysis patients. Nephron 40:440-445, 1985.
39. Roca AO, Jarjoura D, Blend D, et al: Dialysis leg cramps. Efficacy of quinine versus vitamin E. ASAIO J 38:M481-M485, 1992.
40. Roberts HJ: Perspective on vitamin E as therapy. JAMA 246: 129-131, 1981.
41. Suttie JW: Vitamin K. IN Handbook of Vitamins (2nd ed.), Machlin LJ, (ed). Marcel Dekker, New York, 1991, pp 145-194.
42. Fukagawa M, Kitaoka M, Fukada N, et al: Pathogenesis and mangement of parathyroid hyperplasia in chronic renal failure: Role of calcitriol. Min Electro Metab 21:97-100, 1995.
43. 2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. JASN 9:1427-1432, 1998.
44. Kopple JD, Swenseid ME: Nutrition in patients undergoing maintenance hemodialysis. Kid Int 8(Suppl2):79-84, 1975.
45. Prasad AS, Oberleas D: Binding of zinc to amino acids and serum proteins in vitro. J Lab Clin Med 76:416-425, 1970.
46. Flynn A, Pories WJ, Strain WH, et al: Rapid serum-zinc depletion associated with corticosteroid therapy. Lancet II:1169-1172, 1971.
47. Prasad AS, Schoomacker EB, Ortega J, et al: Zinc deficiency in sickle cell disease. Clin Chem 21:582-587, 1975.
48. Prasad AS, Halsted JA, Nadimi M: Syndrome of iron deficiency anemia, hepatosplenomegaly, hypogonadism, dwarfism, and geophagia. Am J Med 31:532-546, 1961.
49. Henkin RI, Scheichter PF, Friedewald WT, et al: A double-blind study of the effects of zinc sulfate on taste and smell function. Am J Med Sci. 272:285-299, 1976.
50. Mahajan SK, Bowersox EM, Rye DL, et al: Factors underlying abnormal zinc metabolism in uremia. Kid Int 36(Suppl. 27): S269-S273, 1989.
51. Antoniou LD, Shalhour RJ, Sudhakar T, et al: Revresal of urarmic impotence by zinc. Lancet:895-898, October 1977.
52. Mahajan SK, Abbasi AA, Prasad AS, et al: Effect of oral zinc therapy on gonadal function in hemodialysis patients. Ann Int Med Sep 97:357-361, 1982.
53. Mahajan SK, Prasad AS, Lambujon J, et al: Improvement of uremic hypogeusia by zinc: A double-blind study. Am J Clin Nutr 33:1517-1521, 1980.
54. Atkin-Thor E, Goddard BW, O'Nion J, et al: Hypogeusia and zinc depletion in chronic dialysis patients. Am J Clin Nutr 31:1948-1951, 1978.
55. Zetin M, Stone RA: Effects of zinc in chronic hemodialysis. Clin Nephr 13:20-25, 1980.
56. Brook AC, Ward MK, Cook DB, et al: Absence of a therapeutic effect of zinc in the sexual dysfunction of haemodialysed patients. Lancet 20:618-620, 1980.
57. Vreman HJ, Venter C, Leegwater J, et al: Taste, smell and zinc metabolism in patients with chronic renal failure. Nephron 26:163-170, 1980.
58. Song MK, Adham NF: Determination of native zinc content of alpha-2-macroglobulin in normal, hyperzincemic and hypozince-mic sera by sucrose density gradient centrifugation. Clin Chim Acta 99:13-21, 1979.
59. Dasgupta A, Peng Y: Dialyzability and binding of digoxin-like immunoreactive factors (DLIF) with serum macromolecules in uremic patients on hemodialysis. Life Sci 49:1603-1609, 1991.
60. Zumkley H, Bertram HP, Vetter H, et al: Zinc concentrations in plasma and erythrocytes in digitalized patients. Klin Wochenschr 59:1345-1347.
61. Keyou G, Zue A, Bai J, et al: Keshan disease-An endemic cardiomyopathy in China. Virchows Arch (Pathol Anat) 401:1-15, 1983.
62. Fleming CR, Lie JT, McCall JT, et al: Selenium deficiency and fatal cardiomyopathy in a patient on home parenteral nutrition. Gastroenterol 83:689-693, 1982.
63. Leung A, Henderson I, Fell G, et al: Selenium deficiency in chronic uraemia and dialysis. Proc EDTA-ERA 22:1134-1138, 1985.
64. Kostakopoulos A, Kotsalos A, Alexopoulos J, et al: Serum selenium levels in healthy adults and its changes in chronic renal failure. Int Urol Nephrol 22:397-401, 1990.
65. Girelli D, Olivieri O, Stanzial AM, et al: Low platelet glutathione peroxidase activity and serum selenium concentration in patients with chronic renal failure: Relations to dialysis treatments, diet and cardiovascular complications. Clin Sci (Colch) 84:611-617, 1993.
66. Napolitano G, Bonomini M, Bomba G, et al: Thyroid function and plasma selenium in chronic uremic patients on hemodialysis treatment. Biol Trace Elem Res 55:221-230, 1996.
67. Bonomini M, Forster S, Manfrini V, et al: Geographic factors and plasma selenium in uremia and dialysis. Nephron 72:197-204, 1996.
68. Milly K, Wit L, Diskin C, et al: Selenium in renal failure patients. Nephron 61:139-144, 1992.
69. Alfrey AC, LeGendre GR, Kaehny WD: The dialysis encephalopathy syndrome: Possible aluminum intoxication. N Eng J Med 294:184-188, 1976.
70. Kaehny WD, Alfrey AC, Holman RE, et al: Aluminum transfer during hemodialysis. Kid Int 12:361-365, 1977.
71. Parkinson IS, Ward MK, Feest TG, et al: Fracturing dialysis osteodystrophy and dialysis encephalopathy: an epidemiological survey. Lancet I:406-409, 1979.
72. Cournot-Witmer G, Zingraff J, Plachot JJ, et al: Aluminum localization in bone from hemodialyzed patients: Relationship to matrix mineralization. Kid Int 20:375-385, 1981.
73. Hodsmen AB, Sherrard DJ, Alfrey AC, et al: Bone aluminum and histomorphometric features of renal osteodystrophy. J Clin Endocrinol Metab 54:539-546, 192.
74. Sherrard DJ: Aplastic bone: A nondisease of medical progress. Adv Ren Replace Ther 2:20-23, 1995.
75. Touam M, Martinez F, Lacour B, et al: Aluminum-induced, reversible microcytic anemia in chronic renal failure: Clinical and experimental studies. Clin Nephrol 19:295-298, 1983.
76. Alfrey AC: Aluminum and renal disease. Contrib Nephrol 102: 110-124, 1993.
77. King S, Wills M, Savory J: Serum binding of aluminum. Res Commun Chem Pathol Pharmacol 26:161-169, 1979.
78. Khalil-Manesh F, Agness C, Gonick HC: Aluminum-binding protein in dialysis dementia. I. Characterization in plasma by gel chromatography and electrophoresis. Nephron 52:323-328, 1989.
79. Khalil-Manesh F, Agness C, Gonick HC: Aluminum-binding protein in dialysis dementia. II. Characterization in plasma by ultrafiltration. Nephron 52:329-333, 1989.
80. Milliner DS, Nebeker HG, Ott SM, et al: Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. Ann Int Med 101:775-780, 1984.
81. Boelaert JR, Fenves AZ, Coburn JW: Deferoxamine therapy and mucormycosis in dialysis patients: Report of an international registry. Am J Kid Dis 18:660-667, 1991.
82. deLocht M, Boelaert JR, Schneider YJ: Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol 47:1843-1850, 1994.
83. Eijgenraam FJ, Donckenvolcke RA: Treatment of iron overload in children and adolescents on chronic haemodialysis. Eur J Pediatr 149:359-362, 1990.
84. Hughes RT, Smith T, Hesp R, et al: Regulation of iron absorption in iron loaded subjects with end stage renal disease: Effects of treatment with recombinant human erythropoietin and reduction of iron stores. Br J Haemaatol 82:445-454, 1992.
85. Barany P, ERiksson LC, Hultcrantz R, et al: Serum ferritin and tissue iron in anemic dialysis patients. Miner Electrolyte Metab 23:273-276, 1997.
86. DeMarchi S, Cecchin E: Hepatic computed tomography for monitoring the iron status of haemodialysis patients with haemosiderosis treated with recombinant human erythropoietin. Clin Sci (Colch) 81:113-121, 1991.
87. el-Reshaid K, Seshadri MS, Hourani H, et al: Endocrine abnormalities in hemodialysis patients with iron overload: Reversal with iron depletion. Nutr 11(Suppl):521-526, 1995.
88. Van de Vyver FL, Visser WJ, D'Haese PC, et al: Iron overload and bone disease in chronic dialysis patients. Nephrol Dial Transplant 5:781-787, 1990.
89. Parry R, Plowman D, Delves HT, et al: Silicon and aluminium interactions in haemodialysis patients. Nephrol Dial Transplant 13:1759-1762, 1998.
90. Hosokawa S, Yoshida O: Silicon level in rats with chronic renal failure produced by 5/6 nephrectomy. Nephron 69:301-304, 1995.
91. Saldanha LF, Gonick HC, Rodriguez HJ, et al: Silicon-related syndrome in dialysis patients. Nephron 77:48-56, 1997.
92. Hershey CO, Ricanati ES, Hershey LA, et al. Silicon as a potential uremic neurotoxin: Trace element analysis in patients with renal failure. Neurology 33:786-791, 1983.
93. Berlyne G, Dudek E, Adler AJ, et al: Silicon metabolism: The basic facts in renal failure. Kid Int 28(Suppl 17):S175-S177, 1983.
94. Gitelman HJ, Alderman FR, Perry SJ: Silicon accumulation in dialysis patients. Am J Kid Dis 19:140-143, 1992.
95. Dobbie JW, Smith MB: Urinary and serum silicon in normal and uraemic individuals. Ciba Found Symp 121:194-213, 1986.
96. Hosokawa S, Morinaga M, Nishitani H, et al: Silicon in chronic hemodialysis patients. Trans Am Soc Artif Intern Organs XXXII: 260-264, 1987.
97. Van de Vyver FL, D'Haese PC, Visser WJ, et al: Bone lead in dialysis patients. Kid Int 33:601-607, 1988.
98. Hu H: Bone lead as a new biologic marker of lead dose: Recent findings and implications for public health. Environ Health Perspectives 106(Suppl 4):961-967, 1998.
99. Wedeen RP: Bone lead, hypertension, and lead nephropathy. Environ Health Perspect 78:57-60, 1988.
100. Adachi JD, Arlen D, Webber CE, et al: Is there any association between the presence of bone disease and cumulative exposure to lead? Calcif Tissue Int 63:429-432, 1998.
101. Gonick HC, Alexander GV: Trace element abnormalities in chronic uremia. NIAMDD Report #AK-3-6-2212-F, 1977.
102. Kessler M, Durand PY, Hestin D, et al: Elevated body lead burden from drinking water in end-stage chronic renal failure. Nephrol Dial Transplant 10:1648-1653, 1995.
103. Sondheimer JH, Mahajan SK, Rye DL, et al: Elevated plasma copper in chronic renal failure. Am J Clin Nutr 47:896-899, 1988.
104. Barbour BH, Bischel M, Abrams DE: Copper accumulation in patients undergoing chronic hemodialysis. The role of cuprophan. Nephron 8:455-462, 1971.
105. Chugh KS, Sharma BK, Singhai PC, et al: Acute renal failure following copper sulphate intoxication. Postgrad Med J 53:18-23, 1977.